<DOC>
	<DOC>NCT00235872</DOC>
	<brief_summary>The purpose of the study is to assess the long-term safety and tolerability of repeated administration of adalimumab in Japanese subjects with rheumatoid arthritis.</brief_summary>
	<brief_title>Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Participation and completion until Week 24 of the prior adalimumab doseranging study. Females must be postmenopausal for at least 1 year, surgically sterile, or practicing birth control throughout the study and for 90 days after study completion. Female subjects tested negative in pregnancy test (serum test) at Week 24 in prior adalimumab study, if capable of pregnancy. A subject who experienced any of the following during prior study: Advanced or poorly controlled diabetes Joint surgery (joint evaluated in this study) A subject who has been prescribed excluded medications during prior study. History of following during prior study: Clinically significant drug or alcohol abuse Intravenous (iv) drug abuse Active infection with listeria or tuberculosis (TB) Lymphoma, leukemia And, any malignancy with the exception of successfully treated nonmetastatic basal cell carcinoma of the skin. A subject who has been administered a live vaccine during prior study, or subject scheduled to complete the administration of a live vaccine during the study period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>